GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » Forward PE Ratio

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Forward PE Ratio : 0.00 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals Forward PE Ratio?

Clementia Pharmaceuticals's Forward PE Ratio for today is 0.00.

Clementia Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Clementia Pharmaceuticals's PE Ratio for today is 0.00.


Clementia Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Clementia Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clementia Pharmaceuticals Forward PE Ratio Chart

Clementia Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Clementia Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Clementia Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Clementia Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clementia Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clementia Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Clementia Pharmaceuticals's Forward PE Ratio falls into.



Clementia Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Clementia Pharmaceuticals  (NAS:CMTA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Clementia Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Clementia Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Headlines

From GuruFocus

Clementia Announces Pricing of Public Offering of Common Shares

By GlobeNewswire GlobeNewswire 10-30-2018

Clementia Announces the Departure of Chief Commercial Officer

By Marketwired Marketwired 11-30-2018